+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Granisetron Market by Dosage Form, Application, Distribution Channel, End User, Product Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6017482
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Granisetron Market grew from USD 7.43 billion in 2024 to USD 7.95 billion in 2025. It is expected to continue growing at a CAGR of 6.69%, reaching USD 10.97 billion by 2030.

Uncovering Granisetron’s Role in Modern Therapeutics and Its Significance for Managing Nausea and Vomiting Across Diverse Clinical Applications

Granisetron stands at the forefront of antiemetic therapy, establishing itself as a pivotal treatment for patients experiencing nausea and vomiting associated with chemotherapy, surgical procedures, and radiation therapy. As a highly selective 5-hydroxytryptamine type 3 receptor antagonist, it mitigates emesis by inhibiting serotonin signaling within the central nervous system and gastrointestinal tract. Over the past two decades, mounting clinical evidence has underscored its efficacy and favorable tolerability relative to earlier antiemetic agents, driving widespread adoption within oncology protocols. Moreover, the maturation of pharmacokinetic profiles-characterized by rapid absorption, prolonged half-life, and minimal drug-drug interactions-has positioned granisetron as a versatile option for diverse treatment settings. In addition, the expansion of oral disintegrating tablets and optimized infusion regimens has enabled greater outpatient management, reducing healthcare burdens and enhancing patient quality of life.

Transitioning beyond traditional intravenous bolus and infusion models, market stakeholders are actively exploring novel delivery systems, including subcutaneous formulations and extended-release technologies, to further improve adherence and therapeutic consistency. Regulatory approvals across key regions have catalyzed this innovation trajectory, while ongoing research endeavors aim to refine dosing paradigms and uncover new applications. Simultaneously, a rising global cancer burden, increasing frequency of ambulatory surgeries, and an expanding elderly population underscore the sustained need for effective antiemetic interventions. Despite these growth drivers, challenges persist in balancing cost pressures with equitable access, particularly in emerging economies where distribution infrastructure and reimbursement frameworks vary widely. Consequently, strategic collaborations among pharmaceutical developers, healthcare providers, and payers are essential to navigate complex market dynamics and ensure that granisetron remains an indispensable component of contemporary clinical practice.

Exploring How Recent Developments and Innovations Are Reshaping the Granisetron Market Landscape and Influencing Treatment Protocols Worldwide

Over the past several years, the granisetron market has undergone a profound transformation driven by technological advances, evolving clinical protocols, and shifting patient expectations. The integration of digital health solutions has enabled providers to monitor emesis episodes in real time, leveraging mobile applications and wearable sensors. This data-driven approach not only facilitates personalized dosing adjustments but also enhances patient engagement and adherence. Simultaneously, the emergence of artificial intelligence in predictive modeling has empowered clinicians to anticipate individual risk factors for chemotherapy-induced nausea and vomiting, thereby optimizing prophylactic strategies.

Moreover, regulatory shifts in major markets have accelerated the approval of novel formulations that prioritize convenience and sustained release. Oral disintegrating tablets and subcutaneous delivery systems have transitioned from experimental concepts to mainstream options, reflecting a pivot toward outpatient care paradigms. In parallel, strategic alliances between pharmaceutical innovators and contract manufacturing organizations have streamlined supply chains, ensuring rapid scale-up of production while maintaining stringent quality standards. Collectively, these developments have redefined competitive dynamics, compelling market participants to adopt agile approaches that blend scientific innovation with patient-centric service models.

Analyzing the Ripple Effects of New United States Tariffs on Granisetron Imports and Supply Chains Throughout 2025 and Beyond

In early 2025, the introduction of revised United States tariffs on pharmaceutical imports has instigated a recalibration of supply chain strategies and cost structures within the granisetron market. Traditionally reliant on global contract manufacturing for active pharmaceutical ingredients, manufacturers are now evaluating alternative sourcing destinations to mitigate exposure to import duties. This has prompted exploratory partnerships in regions with favorable trade agreements, as stakeholders seek to stabilize API procurement costs and maintain consistent supply levels.

The tariff adjustments have also influenced pricing negotiations across distribution channels, as wholesalers and pharmacies reassess margin expectations. Healthcare providers are adapting by consolidating purchasing agreements and expanding direct-to-patient delivery options to offset any incremental cost burdens. Concurrently, the transition toward domestic manufacturing capabilities has gained momentum, with several organizations accelerating investment in local production facilities. While these shifts engender short-term operational challenges, they present an opportunity for the industry to fortify supply chain resilience and enhance long-term sustainability. Ultimately, the cumulative impact of the 2025 United States tariffs underscores the necessity for adaptive strategies that balance economic considerations with uninterrupted patient access.

Strategic Segmentation Analysis Highlighting How Dosage Form Application Distribution Channels End Users and Product Types Drive Market Dynamics

Insight into market segmentation reveals that dosage form diversification is a central determinant of granisetron adoption across clinical settings. The injection segment encompasses both intravenous bolus and intravenous infusion modalities, catering to acute care and controlled administration scenarios. Simultaneously, the advent of oral disintegrating tablets has introduced a convenient alternative for outpatient management, while the standard tablet format continues to serve conventional dosing requirements. This multifaceted dosage landscape enables healthcare providers to tailor antiemetic regimens according to patient acuity and treatment environment.

Equally significant is the application-based segmentation, where chemotherapy-induced nausea and vomiting constitutes a critical focus area, further delineated by acute phase and delayed phase management. Postoperative nausea and vomiting represents a distinct therapeutic domain, as does radiation-induced emesis, each demanding specialized prophylactic and rescue therapies. Distribution channel analysis highlights the interplay among hospital pharmacies, online pharmacies and retail pharmacies in shaping accessibility and fulfillment models. End users such as ambulatory surgical centers, clinics and hospitals drive demand patterns through their respective procedural volumes and formulary decisions. Finally, the competitive landscape is influenced by the presence of both branded and generic product types, with patent expirations and formulary shifts fostering a dynamic environment for market entrants and incumbent players alike.

Regional Dynamics and Growth Patterns Revealed Through Insights Across the Americas Europe Middle East Africa and Asia Pacific Granisetron Markets

Regional dynamics within the granisetron market showcase divergent growth trajectories shaped by healthcare infrastructure, regulatory environments and patient demographics. In the Americas, established oncology and surgical care frameworks support broad adoption of advanced antiemetic therapies, with robust insurance reimbursement facilitating access across inpatient and outpatient settings. North American markets are characterized by dynamic pricing negotiations and an emphasis on value-based care models, driving innovation in delivery mechanisms and patient support programs.

Across Europe, the Middle East and Africa, heterogeneous regulatory pathways and varying reimbursement policies create a complex mosaic of market access challenges and opportunities. Western European countries exhibit high penetration of novel formulations, whereas certain emerging markets within EMEA prioritize cost-effective generic alternatives. In parallel, regional initiatives aimed at harmonizing pharmaceutical regulations are gradually streamlining approval timelines, fostering cross-border collaborations and investment in local manufacturing hubs. The Asia-Pacific region demonstrates rapid growth potential underpinned by rising cancer incidence, expanding surgical volumes and increasing healthcare expenditure. However, disparities in distribution infrastructure and out-of-pocket payment burdens necessitate tailored commercialization strategies to ensure equitable reach and sustained market expansion.

Profiling Leading Industry Players and Emerging Competitors Shaping the Competitive Granisetron Market Landscape with Innovation and Strategic Partnerships

An examination of leading companies in the granisetron market underscores a competitive landscape defined by strategic innovation and global outreach. Established pharmaceutical firms with robust research and development pipelines have prioritized next-generation delivery systems, including extended-release subcutaneous formulations and novel oral disintegrating variants, to differentiate their offerings. Meanwhile, prominent generic manufacturers have leveraged cost-effective production platforms and aggressive market penetration tactics to capture share in price-sensitive segments.

Partnership agreements between innovator companies and contract manufacturing organizations have facilitated efficient scale-up of granisetron production while ensuring compliance with evolving quality standards. Several key players are also investing in clinical studies to explore off-label indications and combination therapies that enhance antiemetic efficacy. Geographic expansion through targeted acquisitions and licensing arrangements has further solidified these companies’ positions in emerging markets. The competitive interplay among branded innovators, large-scale generics and specialized biotech firms has intensified the pursuit of value-added services, such as patient assistance programs and digital adherence tools, reflecting a holistic approach to market leadership.

Actionable Strategies and Best Practices for Manufacturers Distributors and Healthcare Institutions to Navigate Complexities and Capture Growth in Granisetron Market

To navigate the complexities of the granisetron market and capitalize on emerging opportunities, industry leaders should first strengthen supply chain resilience by diversifying API sourcing and forging strategic alliances across multiple geographies. Establishing regional manufacturing capabilities or entering into joint ventures can mitigate the effects of trade policy fluctuations and ensure robust production continuity. Additionally, prioritizing formulation innovation-such as developing user-friendly oral disintegrating tablets and long-acting injectables-will address evolving patient preferences and care delivery trends.

Beyond product development, manufacturers and distributors must adopt value-based pricing frameworks aligned with healthcare provider and payer expectations to demonstrate cost-effectiveness and clinical benefits. Collaborative partnerships with healthcare institutions can facilitate real-world evidence generation, reinforcing granisetron’s therapeutic impact. Incorporating digital health platforms to track patient outcomes and improve adherence presents another avenue for differentiation while supporting data-driven decision making. Finally, proactive engagement with regulatory bodies and advocacy groups will expedite formulary listings and reimbursement approvals, enabling faster market penetration and sustainable growth.

Comprehensive Research Framework Detailing Data Sources Analytical Techniques and Validation Processes Underpinning the Granisetron Market Analysis

The research methodology underpinning this report integrates both primary and secondary data sources to deliver comprehensive market insights and ensure analytical rigor. Primary research comprised in-depth interviews with key opinion leaders, including oncologists, anesthesiologists and pharmacy directors, as well as structured surveys with pharmaceutical executives and supply chain managers. Secondary research involved systematic reviews of regulatory filings, peer-reviewed literature, clinical trial registries and industry conference proceedings to corroborate market developments.

Data triangulation techniques were employed to validate findings across multiple sources and minimize potential biases. Quantitative analyses leveraged statistical modeling to assess segmentation trends, regional dynamics and competitive benchmarks. A Delphi panel of subject matter experts provided iterative feedback on emerging hypotheses, refining the analytical framework and ensuring alignment with real-world practice. Quality assurance processes, including cross-validation of data points and consistency checks, were conducted throughout the study to maintain the highest standards of accuracy and reliability.

Synthesizing Key Findings and Future Outlook to Provide a Cohesive Synopsis of Critical Insights and Their Implications for the Granisetron Market

In summary, the granisetron market stands at a pivotal juncture marked by rapid innovation, shifting trade policies and increasingly sophisticated segmentation strategies. The convergence of novel delivery systems, digital health integration and diverse application areas underscores the therapeutic versatility of granisetron. However, stakeholders must remain vigilant in addressing supply chain vulnerabilities exposed by tariff reforms and in navigating regional regulatory complexities to sustain momentum.

Looking ahead, the balance between branded innovation and generic competition will continue to shape market dynamics, while ongoing clinical research holds the promise of expanding granisetron’s role in emerging treatment paradigms. Key growth drivers include the continued rise in cancer and surgical procedure volumes, as well as the global imperative to improve patient quality of life. By synthesizing these critical insights, industry participants can formulate strategic initiatives that align with evolving stakeholder expectations and drive long-term value creation.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Dosage Form
    • Injection
      • Intravenous Bolus
      • Intravenous Infusion
    • Oral Disintegrating Tablet
    • Tablet
      • Standard
  • Application
    • Chemotherapy-Induced Nausea And Vomiting
      • Acute Phase
      • Delayed Phase
    • Postoperative Nausea And Vomiting
    • Radiation-Induced Nausea And Vomiting
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Hospitals
  • Product Type
    • Branded
    • Generic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Limited
  • Sandoz International GmbH
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Limited
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Fresenius Kabi AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Surge in approvals of generic granisetron injectable formulations driving price competition and market access expansion
5.2. Adoption of transdermal granisetron patches in radiotherapy induced nausea management enhancing patient convenience and compliance
5.3. Rising integration of granisetron into novel combination antiemetic regimens improving control of chemotherapy induced nausea and vomiting
5.4. Expansion of granisetron use in emerging markets following favorable reimbursement policies and growing oncology treatment infrastructure
5.5. Development of novel sustained release granisetron delivery technologies targeting improved efficacy and reduced dosing frequency
5.6. Impact of biosimilar entrants on branded granisetron sales dynamics and strategic portfolio adaptations by leading manufacturers
5.7. Key regulatory milestones and label expansions broadening granisetron indications to include postoperative nausea and vomiting prevention
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Granisetron Market, by Dosage Form
8.1. Introduction
8.2. Injection
8.2.1. Intravenous Bolus
8.2.2. Intravenous Infusion
8.3. Oral Disintegrating Tablet
8.4. Tablet
8.4.1. Standard
9. Granisetron Market, by Application
9.1. Introduction
9.2. Chemotherapy-Induced Nausea And Vomiting
9.2.1. Acute Phase
9.2.2. Delayed Phase
9.3. Postoperative Nausea And Vomiting
9.4. Radiation-Induced Nausea And Vomiting
10. Granisetron Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Granisetron Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.4. Hospitals
12. Granisetron Market, by Product Type
12.1. Introduction
12.2. Branded
12.3. Generic
13. Americas Granisetron Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Granisetron Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Granisetron Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Teva Pharmaceutical Industries Limited
16.3.3. Sandoz International GmbH
16.3.4. Viatris Inc.
16.3.5. Dr. Reddy’s Laboratories Limited
16.3.6. Cipla Limited
16.3.7. Sun Pharmaceutical Industries Limited
16.3.8. Glenmark Pharmaceuticals Limited
16.3.9. Hikma Pharmaceuticals PLC
16.3.10. Fresenius Kabi AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GRANISETRON MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GRANISETRON MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GRANISETRON MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GRANISETRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GRANISETRON MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GRANISETRON MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GRANISETRON MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GRANISETRON MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GRANISETRON MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GRANISETRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GRANISETRON MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GRANISETRON MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GRANISETRON MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GRANISETRON MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GRANISETRON MARKET: RESEARCHAI
FIGURE 26. GRANISETRON MARKET: RESEARCHSTATISTICS
FIGURE 27. GRANISETRON MARKET: RESEARCHCONTACTS
FIGURE 28. GRANISETRON MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GRANISETRON MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GRANISETRON MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GRANISETRON MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GRANISETRON MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GRANISETRON MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GRANISETRON MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS BOLUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS BOLUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GRANISETRON MARKET SIZE, BY ORAL DISINTEGRATING TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GRANISETRON MARKET SIZE, BY ORAL DISINTEGRATING TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GRANISETRON MARKET SIZE, BY STANDARD, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GRANISETRON MARKET SIZE, BY STANDARD, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GRANISETRON MARKET SIZE, BY ACUTE PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GRANISETRON MARKET SIZE, BY ACUTE PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GRANISETRON MARKET SIZE, BY DELAYED PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GRANISETRON MARKET SIZE, BY DELAYED PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GRANISETRON MARKET SIZE, BY POSTOPERATIVE NAUSEA AND VOMITING, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GRANISETRON MARKET SIZE, BY POSTOPERATIVE NAUSEA AND VOMITING, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GRANISETRON MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GRANISETRON MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GRANISETRON MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GRANISETRON MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GRANISETRON MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GRANISETRON MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GRANISETRON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GRANISETRON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GRANISETRON MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GRANISETRON MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GRANISETRON MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GRANISETRON MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GRANISETRON MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GRANISETRON MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS GRANISETRON MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES GRANISETRON MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES GRANISETRON MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 100. CANADA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 101. CANADA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 102. CANADA GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 103. CANADA GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 104. CANADA GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 105. CANADA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 107. CANADA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 108. CANADA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 109. CANADA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. CANADA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. CANADA GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. CANADA GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. CANADA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. CANADA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. MEXICO GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 116. MEXICO GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 117. MEXICO GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 118. MEXICO GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 119. MEXICO GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 120. MEXICO GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 121. MEXICO GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 124. MEXICO GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 125. MEXICO GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. MEXICO GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. MEXICO GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. MEXICO GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. MEXICO GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. MEXICO GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 197. GERMANY GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 198. GERMANY GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 199. GERMANY GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 200. GERMANY GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 201. GERMANY GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 202. GERMANY GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 203. GERMANY GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 204. GERMANY GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 205. GERMANY GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 206. GERMANY GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 207. GERMANY GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. GERMANY GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. GERMANY GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. GERMANY GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. GERMANY GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. GERMANY GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. FRANCE GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 214. FRANCE GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 215. FRANCE GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 216. FRANCE GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 217. FRANCE GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 218. FRANCE GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 219. FRANCE GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 220. FRANCE GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 221. FRANCE GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 222. FRANCE GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 223. FRANCE GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. FRANCE GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. FRANCE GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. FRANCE GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. FRANCE GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 228. FRANCE GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. ITALY GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 246. ITALY GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 247. ITALY GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 248. ITALY GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 249. ITALY GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 250. ITALY GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 251. ITALY GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. ITALY GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. ITALY GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 254. ITALY GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 255. ITALY GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. ITALY GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. ITALY GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. ITALY GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. ITALY GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 260. ITALY GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 261. SPAIN GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 262. SPAIN GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 263. SPAIN GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 264. SPAIN GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 265. SPAIN GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 266. SPAIN GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 267. SPAIN GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 268. SPAIN GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 269. SPAIN GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 270. SPAIN GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 271. SPAIN GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. SPAIN GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. SPAIN GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. SPAIN GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. SPAIN GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 276. SPAIN GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 310. SOUTH AFRICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 325. DENMARK GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 326. DENMARK GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 327. DENMARK GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 328. DENMARK GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 329. DENMARK GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 330. DENMARK GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 331. DENMARK GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 332. DENMARK GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 333. DENMARK GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 334. DENMARK GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 335. DENMARK GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 336. DENMARK GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 337. DENMARK GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 338. DENMARK GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 339. DENMARK GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 340. DENMARK GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 341. NETHERLANDS GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 342. NETHERLANDS GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 343. NETHERLANDS GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 344. NETHERLANDS GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 345. NETHERLANDS GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 346. NETHERLANDS GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 347. NETHERLANDS GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 348. NETHERLANDS GRANISETRON MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 349. NETHERLANDS GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2024 (USD MILLION)
TABLE 350. NETHERLANDS GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2025-2030 (USD MILLION)
TABLE 351. NETHERLANDS GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 352. NETHERLANDS GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 353. NETHERLANDS GRANISETRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 354. NETHERLANDS GRANISETRON MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 355. NETHERLANDS GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 356. NETHERLANDS GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 357. QATAR GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 358. QATAR GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 359. QATAR GRANISETRON MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 360. QATAR GRANISETRON MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 361. QATAR GRANISETRON MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 362. QATAR GRANISETRON MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Granisetron market report include:
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Limited
  • Sandoz International GmbH
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Limited
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Fresenius Kabi AG

Table Information